Biotechs outline their IPO plans

Plenty of IPO news today in biotech today. Here it is in a nutshell:

- Jazz Pharmaceuticals, which made a name for itself gathering a huge amount of venture capital, has filed an IPO designed to raise $137 million through the sale of six million shares. The money is earmarked for the launch of its OCD drug Luvox CR along with late-stage trials of its pain drug JZP-6 as well as new research into other programs. Jazz raised $265 million from venture groups.

- Amicus Therapeutics has priced its IPO of 5 million shares at $14 to $16 a share.

- And Eurand has priced its IPO of seven million shares at $16 per.

- here's the AP report on Jazz
- here's StreetInsider's report on Amicus
- and here's the release on Eurand

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.